Unichem Laboratories Limited (NSE:UNICHEMLAB)
372.60
+5.45 (1.48%)
May 22, 2026, 3:29 PM IST
Unichem Laboratories Revenue
In the fiscal year ending March 31, 2026, Unichem Laboratories had annual revenue of 22.65B INR with 7.29% growth. Unichem Laboratories had revenue of 5.99B in the quarter ending March 31, 2026, with 1.94% growth.
Revenue
22.65B
Revenue Growth
+7.29%
P/S Ratio
1.16
Revenue / Employee
7.21M
Employees
3,142
Market Cap
26.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 22.65B | 1.54B | 7.29% |
| Mar 31, 2025 | 21.11B | 3.26B | 18.25% |
| Mar 31, 2024 | 17.85B | 4.42B | 32.92% |
| Mar 31, 2023 | 13.43B | 731.90M | 5.76% |
| Mar 31, 2022 | 12.70B | 346.97M | 2.81% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.45B |
| Aarti Pharmalabs | 18.01B |
| Innova Captab | 16.37B |
| Solara Active Pharma Sciences | 13.75B |
| Windlas Biotech | 9.22B |
| Orchid Pharma | 8.11B |
| RPG Life Sciences | 7.08B |
| Ind-Swift Laboratories | 5.94B |
Unichem Laboratories News
- 8 months ago - Unichem Laboratories shares fall 3% after €19.49 million EU penalty demand in perindopril case - Business Upturn
- 9 months ago - Unichem Pharmaceuticals recalls mislabeled Cyclobenzaprine tablets in US over safety concerns - Business Upturn
- 9 months ago - Unichem Laboratories’ Roha API facility gets VAI classification from USFDA - Business Upturn
- 11 months ago - Unichem Laboratories shares drop 4% after USFDA flags 3 procedural issues at Roha facility - Business Upturn
- 1 year ago - Unichem Labs Q4 Results: Revenue up 27.9% YoY to Rs 587.18 crore, company swings back to net profit - Business Upturn
- 1 year ago - Unichem Laboratories receives USFDA EIR for Pithampur facility; inspection classified as VAI - Business Upturn
- 1 year ago - Unichem Laboratories shares rise 2.35% as API plant expansion boosts production capacity - Business Upturn
- 1 year ago - Unichem Laboratories completes Phase I expansion of API plant at Pithampur with Rs 200 crore investment - Business Upturn